Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

ClinicalTrials.gov ID: NCT03777982

Public ClinicalTrials.gov record NCT03777982. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase III Study - Conventional Androgen Deprivation Therapy With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and Androgen Deprivation Therapy

Study identification

NCT ID
NCT03777982
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Dana-Farber Cancer Institute
Other
Enrollment
12 participants

Conditions and interventions

Interventions

  • Prednisone Drug
  • Apalutamide Drug
  • Abiraterone Acetate Drug
  • LHRH Agonist or Antagonist Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 19, 2020
Primary completion
Feb 12, 2024
Completion
Feb 12, 2024
Last update posted
Sep 18, 2024

2020 – 2024

United States locations

U.S. sites
5
U.S. states
1
U.S. cities
3
Facility City State ZIP Site status
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Brigham and Women's Hospital Boston Massachusetts 02215
Dana Farber Cancer Institute Boston Massachusetts 02215
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center Milford Massachusetts 01757
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital South Weymouth Massachusetts 02190

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03777982, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 18, 2024 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03777982 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →